Metabolic Disorders

OTL-200 is an ex vivo autologous hematopoietic stem cell gene therapy.

A regulatory decision is expected by October 8,2023.

Semaglutide is a glucagon-like peptide-1 receptor agonist.

TSHA-102 is an investigational adeno-associated virus 9 gene transfer therapy.

Applying STEP 1 treatment would result in a 46.1% reduction in obesity prevalence and 17.8% relative risk reduction in CVD.

Veopoz is supplied as a 400mg/2mL solution in a single-dose vial.

Glucocorticoids led to 1.1kg more weight gain than control treatment over 2 years using data from 5 pooled RCTs.

Based on body mass index, 120 million Americans would qualify to take Wegovy.

Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.

Despite fewer than one in 10 achieving it, likelihood of 5% or greater weight loss was higher than reaching healthy weight body mass index category.

The table below is a review of notable updates that occurred in July 2023 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Semaglutide is a GLP-1 receptor agonist.

TYRA-300 is an investigational, oral, FGFR3-selective inhibitor.

No change in cardiometabolic risk factors or glycemic control seen over six months.

Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.

Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Wegovy is a glucagon-like peptide-1 receptor agonist.

Increased demand for the drug has resulted in supply interruptions.

The Company has decided to discontinue additional clinical studies of QTORIN 3.9% rapamycin anhydrous gel for pachyonychia congenita.